Rallybio Corporation (RLYB) vs Tonix Pharmaceuticals Holding Corp. (TNXP)

Rallybio Corporation and Tonix Pharmaceuticals Holding Corp. are both Biotechnology companies. Rallybio Corporation and Tonix Pharmaceuticals Holding Corp. are of similar size ($87.6M and $85.6M). Tonix Pharmaceuticals Holding Corp. has negative trailing earnings, so its P/E is not meaningful; Rallybio Corporation trades at 3.3×. Tonix Pharmaceuticals Holding Corp. grew revenue faster over the last twelve months: 196.0% against 1.18%. Rallybio Corporation has the higher net margin (0.00% vs −548.6%) and the lower return on invested capital (−944.4% vs −224.5%). Across the 17 metrics below, Rallybio Corporation leads on 11 and Tonix Pharmaceuticals Holding Corp. on 6.

Valuation

Metric RLYB TNXP Biotechnology median
P/E 3.35 n/m 10.26
P/S 104.84 2.65 9.18
P/B 0.97 0.35 2.05
Price to free cash flow 2.91 n/m 24.81
EV/EBITDA 0.03 0.56 0.65
EV/Sales (0.86) (3.15) 8.98
Earnings yield 29.87% (278.89%) (34.89%)
Free cash flow yield 34.41% (205.28%) (24.52%)

Profitability

Metric RLYB TNXP Biotechnology median
Gross margin 100.00% 83.83% 65.16%
Operating margin 0.00% (568.43%) 0.00%
Net margin 0.00% (548.64%) 0.00%
Free cash flow margin 0.00% (543.29%) 0.00%
Return on equity 34.52% (81.82%) (50.12%)
Return on assets 32.85% (72.34%) (45.60%)
Return on invested capital (944.36%) (224.52%) 0.00%

Growth

Metric RLYB TNXP Biotechnology median
Revenue growth (TTM) 1.18% 196.02% 6.26%
EPS growth (last fiscal year) 85.06% 91.75% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric RLYB TNXP Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 28.87 6.61 4.89
Net debt to EBITDA 1.63 1.68 1.01

Dividend

Metric RLYB TNXP Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric RLYB TNXP Biotechnology median
Market cap 85.61m 87.64m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack